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However, anti-PD-1 therapy is not effec-
tive against all types of cancer and still 
only a minority of patients benefit from 
the ICB.[2e,4] Meanwhile, most of the avail-
able humanized antibodies are produced 
from mice, which require complicated 
design and isolation.[5] As a result, the cost 
of checkpoint antibody therapy remains 
unaffordable for many patients.[5b,6] There-
fore, alternative approaches antagonizing 
the PD-1/PD-L1 inhibitor axis need to be 
exploited.[7]
Natural cell membrane derived vesicles 
such as exosomes, macrovesicles, and cell 
membrane extruded vesicles hold great 
promise for biomedicine.[8] Similarly, 
bioengineering strategies are promising 
ways for the enhancement of anticancer 
immunity.[9] Herein, we engineered cell 
membrane derived nanovesicles (NVs) to 
display PD-1 receptors, which enhance the cancer immuno-
therapy through disrupting the PD-1/PD-L1 immune inhibitory 
axis (Figure 1a). The PD-1 NVs can bind to the surface of tumor 
cells and achieve PD-L1 blockade (Figure 1a–c). This blockade 
is expected to effectively revert the exhausted tumor antigen-
specific CD8+ T cells to attack the tumor cells. In addition, the 
NVs can also serve as carriers for other therapeutics to perform 
combination delivery. Indoleamine 2,3-dioxygenase (IDO) is 
an immunosuppressive molecule overexpressed by tumor and 
DC cells (IDO+ DCs) to limit the proliferation and function of 
Cancer cells resist to the host immune antitumor response via multiple 
suppressive mechanisms, including the overexpression of PD-L1 that 
exhausts antigen-specific CD8+ T cells through PD-1 receptors. Checkpoint 
blockade antibodies against PD-1 or PD-L1 have shown unprecedented clinical 
responses. However, limited host response rate underlines the need to develop 
alternative engineering approaches. Here, engineered cellular nanovesicles 
(NVs) presenting PD-1 receptors on their membranes, which enhance 
antitumor responses by disrupting the PD-1/PD-L1 immune inhibitory axis, 
are reported. PD-1 NVs exhibit a long circulation and can bind to the PD-L1 
on melanoma cancer cells. Furthermore, 1-methyl-tryptophan, an inhibitor of 
indoleamine 2,3-dioxygenase can be loaded into the PD-1 NVs to synergistically 
disrupt another immune tolerance pathway in the tumor microenvironment. 
Additionally, PD-1 NVs remarkably increase the density of CD8+ tumor infiltrating 
lymphocytes in the tumor margin, which directly drive tumor regression.
Cancer immunotherapy aims to leverage the human immune 
system to eliminate cancer cells.[1] Among them, immune check-
point blockade (ICB) targeting the programmed death-1 (PD-1)/
programmed death-ligand 1 (PD-L1) pathway induces remarkable 
clinical responses in various types of cancer, such as melanoma, 
renal cell carcinoma, nonsmall cell lung cancer, and bladder 
cancer.[2] PD-L1 is the ligand of PD-1 receptor and is upregulated 
in cancer cells and immune cells to inhibit the effector T cells.[3] 
Therefore, blocking the interaction between PD-1 and PD-L1 
by antibodies boosts the immune response against cancer cells. 
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effector T cells.[10] Here we encapsulated 1-methyl-tryptophan 
(1-MT), a small molecule inhibitor of IDO into PD-1 NVs to 
simultaneously block the PD-1/PD-L1 axis and overcome the 
inhibitory effects of IDO on effector T cells within the tumor 
microenvironment (TME) (Figure 1c).[11]
To prepare PD-1 NVs, we established HEK 293T cells that 
stably express the mouse PD-1 receptor on the cell mem-
brane. HEK 293T cell line has been widely used in cell biology 
research and biotechnology industry because it can be robustly 
transfected and produces high amount of recombinant pro-
teins.[12] DsRed protein-tag was included in the C-terminal por-
tion of PD-1 receptor protein, which made the protein-tag close 
to the inner leaflet of cell membranes, while the functional 
domain of the receptors is extracellular (Figure 1a). Therefore, 
we cloned the mouse PD-1 receptor cDNA into a mammalian 
expression vector. The transfected HEK 293T cells were selected 
Figure 1. Schematic illustration and characterization of PD-1 blockade cellular NVs for cancer immunotherapy. a) Schematic illustration shows the 
praparation of PD-1 NVs loaded with 1-MT. i) Engineering of HEK 293T cell line stably expressing mouse PD-1 receptors on the cell membranes. ii) 
Harvesting of the cell membrane expressing PD-1 receptors. iii) Preparation of PD-1 NVs through extrusion. iv) Loading 1-MT into PD-1 NVs. b) PD-L1 
exhausts CD8+ T cells by interacting with PD-1 receptors. The expression of IDO is induced by Treg cells, which inhibits the activity of CD8+ T cells. 
MHC-I: major histocompatibility complex class I; TCR: T cell receptor; CTLA4: cytotoxic T-lymphocyte associated protein 4. c) PD-L1 blockade by PD-1 
NVs reverts the exhausted CD8+ cells to attack tumor cells. The release of IDO inhibitor 1-MT also reverts the exhausted CD8+ T cells. d) Establishment 
of HEK 293T cell line stably expressing mouse PD-1 on cell membranes. WGA Alexa-Fluor 488 dye was used to label cell membrane. Scale bar: 10 µm. 
e) The TEM image showed the shape and size of PD-1 NVs. Scale bar: 100 nm. f) Cryoscanning electron microscopy (CSEM) image showed the natural 
shape of the PD-1 NVs (Scale bar: 100 nm). g) The confocal image indicated the existence of DsRed-PD-1 NVs by the red spots. Scale bar: 1 µm. h)
The size distribution of PD-1 NVs measured by dynamic light scattering (DLS) analysis. i) Western blot assay exhibited the expression of mouse PD-1
(mPD-1) receptors on the NVs and whole cell lysate (WCLs) of the stable cell line. Na+K+ ATPase was used as a loading control.
with hygromycin B to establish a stable cell line. Notably, the 
death receptor PD-1 was mainly expressed and localized on the 
cell membranes (Figure 1d). Under the selection pressure of 
hygromycin B, the cell line continued to express DsRed PD-1 
receptors for more than twenty passages (Figure S1, Supporting 
Information). Furthermore, we labeled the cell membranes with 
Alexa-Fluor 488 conjugated wheat germ agglutinin (WGA) to 
confirm the localization of the PD-1 receptors. As expected, the 
red fluorescence o f D sRed p rotein c olocalized w ith g reen fl uo-
rescence of WGA Alexa-Fluor 488 dye on the cell membranes 
(Figure 1d).
Next, the engineered HEK 293T cells were cultured and 
lyzed to isolate the cell membranes. The cell membrane vesicles 
expressing PD-1 receptors were prepared by a serial extrusion of 
vesicles through 0.8 and 0.22 µm pore-sized polycarbonate mem-
brane filters.[13] A fter e xtrusion t hrough t he 0 .8 µm p ore-sized 
polycarbonate membrane filters, major cell membrane vesicles 
(MVs) were obtained. The red-light spots in the confocal image 
demonstrated the existence of DsRed-PD-1 on MVs (Figure S2a, 
Supporting Information). The size distribution of MVs was meas-
ured by the dynamic light scattering (DLS) analysis (Figure S2b,  
Supporting Information). The MVs were then extruded through 
0.22 µm pore-sized polycarbonate membrane filters. T he h ar-
vested NVs were further purified by a density gradient ultracen-
trifugation.[13] Next, we characterized the morphology of the NVs 
by electron microscopy. The negatively stained NVs revealed that 
they were closed vesicles using transmission electron micros-
copy (TEM) (Figure 1e). The NVs were also scanned by the cry-
oscanning electron microscopy (CSEM), which showed that the 
NVs had a spherical shape (Figure 1f). The zeta potential of the 
NVs was determined as −10 mV (Figure S2c, Supporting Infor-
mation). Moreover, the expression of PD-1 receptors on the NVs 
was detected using confocal imaging and western blot. The con-
focal image exhibited red-colored spots indicating the existence 
of DsRed-PD-1 NVs (Figure 1g). DLS analysis showed that the 
average diameter of NVs was around 90–100 nm (Figure 1h).  
Additionally, western blot analysis indicated that the puri-
fied N Vs d isplay t he P D-1 r eceptors ( Figure 1 i). To v erify t hat 
whether the PD-1 receptors maintained an outside-out orienta-
tion on NV surfaces, we performed an immunoprecipitation 
assay (IP). It was demonstrated that the PD-1 antibody pulled 
down the majority of PD-1 NVs, which demonstrated that PD-1 
receptors have a correct outside-out orientation on the most 
PD-1 NVs (Figure S3, Supporting Information).
Cancer cells exhaust antigen-specific CD8+ T cells through 
overexpression of PD-L1 ligands that interact with PD-1 
receptors.[2a] To investigate whether PD-1 NVs bind to melanoma 
cells, we incubated the PD-1 NVs with B16F10 melanoma cells 
in vitro. DsRed proteins fused with PD-1 receptors provided 
red fluorescence, which was used as a fluorescent signal label 
of the PD-1 NVs. WGA Alexa-Fluor 488 dye was used to stain 
the cell membranes of the B16F10 melanoma cells. Remark-
ably, we observed that PD-1 NVs effectively bound around the 
cell membrane surface of B16F10 cells after incubation for 
2 h (Figure 2a). In contrast, Cy5.5 labeled the free NVs had 
low membrane binding affinity (Figure 2a). In addition, we 
also detected the interaction between PD-1 NVs and dendritic 
cells (DCs). PD-1 NVs were incubated with bone marrow-
derived DCs (BMDCs) for 2 h. The confocal image showed that  
DsRed-PD-1 NVs could effectively bind and be internalized by 
the BMDCs after 2 h (Figure 2b). To investigate whether the 
binding of PD-1 NVs on the B16F10 cells was through the 
interaction between PD-1 and PD-L1, we first detect the colocal-
ization between PD-1 receptors on NVs and PD-L1 on B16F10 
cells. PD-1 NVs were incubated with EGFP-PD-L1 expressing 
B16F10 cells for 5 h. Notably, PD-1 NVs were colocalized with 
EGFP-PD-L1 on the B16F10 melanoma cells (Figure 2c). To 
confirm the molecular binding between PD-1 receptors on NVs 
and PD-L1 on the B16F10 cells, we added aPD-L1 antibody 
to block the PD-L1 on the B16F10 cells. The confocal images 
showed that PD-1 NVs binding was dramatically reduced when 
PD-L1 antibody (aPD-L1) was preincubated with the cells 
(Figure S4a, Supporting Information). Moreover, the flow cyto-
metric data also showed that the quantity of PD-1 NVs binding 
with B16F10 cells is significantly reduced when PD-L1 antibody 
was preincubated with the cells (Figure 2d; Figure S4b, Sup-
porting Information). We also employed coimmunoprecipita-
tion (CO-IP) assay to detect the molecular interaction between 
PD-1 receptor and PD-L1. After incubation of the PD-1 NVs 
with B16F10 melanoma cells for 20 h, the cells were harvested. 
PD-1 primary antibody was used to pull down the PD-1 recep-
tors on the NVs. Remarkably, PD-L1 was pulled down together 
with PD-1 receptors by the PD-1 antibody (Figure 2e), indi-
cating that PD-1 NVs physically interact with PD-L1 expressed 
by B16F10 cells. Together, these results substantiated that the 
NVs presenting PD-1 on the surface could effectively interact 
with tumor cells through the binding between PD-1 receptor 
and PD-L1.
To investigate the systemic biodistribution and kinetics of 
PD-1 NVs, we labeled the free NVs and PD-1 NVs with Cy5.5. 
Free NVs and PD-1 NVs were injected into the mice through 
tail-vein. As shown in Figure 2f, the PD-1 NVs had higher blood 
retention compared to the free NVs. The PD-1 NVs exhibited 
32% and 17% overall retention compared to 12% and 1.7% 
retention of the free NVs at 8 and 48 h, respectively. Next, we 
examined the in vivo tissue distribution of PD-1 NVs. B16F10-
tumor-bearing mice received Cy5.5-labeled PD-1 NVs via tail-
vein injection. Notably, we observed the accumulation of Cy5.5 
fluorescence of PD-1 NVs primarily at the liver, kidney, and 
tumor sites (Figure 2g,h). To further assess the biodistribution 
of the PD-1 NVs, we quantified the Cy5.5-labeled NVs in the 
sections of organs and tumors by confocal imaging. The WGA 
Alexa-Fluor 488 dye was used to stain the cell membrane in the 
tissue sections. The distribution of the PD-1 NVs paralleled the 
imaging data showing intensive accumulation of the PD-1 NVs 
in the tumor tissue sections (Figure 2i).
To determine whether the PD-1 NVs promote the mice 
immune response to the melanoma tumor, we established 
a melanoma tumor model in which B16F10-luc cells were 
inoculated subcutaneously in C57BL/6 mice. Five days after 
tumor inoculation, 25 mg (based on protein weight) per kg 
free NVs and 20–30 mg per kg PD-1 NVs were inoculated in 
mice through tail-vein injection. Tumor growth was moni-
tored by measuring both bioluminescence signals and tumor 
size. Notably, the growth of B16F10 tumors was significantly 
delayed in mice treated with PD-1 NVs at the dosage of 20, 25, 
and 30 mg kg−1 (Figure S5, Supporting Information). To con-
firm the in vivo antitumor effect of PD-1 NVs, we employed 
treatment with the administration of the anti-PD-L1 antibody 
as a positive control. The mice were divided into three groups: 
25 mg per kg free NVs (Group 1) and PD-1 NVs (Group 2) 
were injected in mice through the tail vein every three days for 
five cycles. Anti-PD-L1 antibody (aPD-L1, Group 3) was also 
injected into mice at 2 mg kg−1 as a positive control group. 
Tumor growth was monitored using both bioluminescence sig-
nals and tumor size. Of note, PD-1 NVs significantly delay the 
B16F10 melanoma tumor growth, comparable to the treatment 
with aPD-L1 (Figure 3a–c). Consequently, PD-1 NVs improved 
the survival of the mice (Figure 3d), and 20% of mice survived 
more than 60 d upon PD-1 NVs treatment. Moreover, there was 
no obvious weight loss during the treatment (Figure 3e). No 
significant antitumor effects were observed in the mice treated 
with free NVs.
Exhausted CD8+ T cells express inhibitory receptor pro-
teins, including PD-1, TIGIT, LAG3, and TIM3,[14] and have 
reduced capacity to produce immune cytokines, such as IFN-γ 
Figure 2. In vitro biological behavior and in vivo biodistribution of PD-1 NVs. a) DsRed-PD-1 NVs bound on the cell membrane of B16F10 cancer cells. 
PD-1 NVs (50 µg mL−1, protein weight) or PD-1 free NVs labeled with Cy5.5 (50 µg mL−1, protein weight) were incubated with B16F10 cells for 2 h. WGA 
Alexa-Fluor 488 dye was used to detect B16F10 cell membrane (Scar bar: 10 µm). b) DsRed-PD-1 NVs were internalized by DCs. PD-1 NVs (50 µg mL−1) 
were incubated with DCs for 2 h. WGA Alexa-Fluor 488 dye was used to detect DC membrane. Scar bar: 10 µm. c) B16F10 cells were transfected with 
EGFP-PD-L1 plasmid for 20 h, then incubated with PD-1 NVs (50 µg mL−1) for 5 h; the colocalization of PD-1 NVs and PD-L1 proteins were detected 
(Scar bar: 10 µm). The above images are the enlarged ones in the white collar on the underside images. d) The representative flow cytometric analysis images 
of PD-1 NVs binding with B16F10 cells (gated on DsRed+). PD-1 NVs (50 µg mL−1) were incubated with B16F10 cells for 5 h. Or aPD-L1 antibody (20 µg mL−1) 
was incubated with the cells for 4 h before the PD-1 NVs were added in the culture medium as indicated. e) CO-IP and western blot were used to examine the 
interaction between PD-1 (on NVs) and PD-L1 (on B16F10 cells). Immunoprecipitation (IP); Immunoblot (IB). f) Cy5.5 labeled free NVs and PD-1 NVs were 
injected through tail-vein of the mice. Fluorescence was measured at different time points as indicated (n = 3). Error bar, mean ± s.d. g) The IVIS spectrum 
images of distribution of free NVs and PD-1 NVs in tumor and major organs. h) Fluorescence intensity per gram of tissue in tumor and major organs as indicated 
(n = 3). Error bar, mean ± s.d. i) The distribution of PD-1 NVs in the organs and tumor sections was detected using confocal microscope. Scar bar: 100 µm.
Figure 3. In vivo antitumor effect of PD-1 NVs. a) In vivo bioluminescence imaging of the B16F10 melanoma tumor of different mice groups at dif-
ferent time points after the tail-vein injection of free NVs, PD-1 NVs and PD-L1 antibody. Day 0: the day for the first time of treatment. b) Average 
tumor volumes of the treated mice in different groups (n = 7). Error bar, mean ± s.e.m. c) Image of representative tumor extracted from euthanized 
mice of each group. d) Survival curves for the mice received the treatment of PD-1 NVs, PD-L1 antibody, and free NVs (n = 10). e) Body weights of 
mice received the treatment and control mice. Error bar, mean ± s.d. f) IFN-γ levels in serum from mice isolated at day 20 after mice received the first 
indicated treatment (n = 3). Error bar, mean ± s.d. g,h) Representative plots (g) and quantitative analysis (h) of T cells (gated on CD3+ cells) in treated 
tumor analyzed by flow cytometry (n = 3). Error bar, mean ± s.d. i) Representative image and j) quantitative analysis of immunofluorescence staining of 
the tumor sections showing infiltrated CD4+ T cells and CD8+ T cells (n = 3). Error bar, mean ± s.d. Scar bar: 100 µm. Throughout, NS: no significant, 
*P < 0.05, **P < 0.01, ***P < 0.001; by one-way analysis of variance (ANOVA) with b,f,h,j) Tukey post-hoc tests or by d) Log-Rank (Mantel-Cox) test.
and TNF-α.[15] To assess whether PD-1 NVs treatment reduces 
T cell exhaustion and maintain their antitumor function, we 
measured IFN-γ and TNF-α levels in the serum of the treated 
mice by the end of the fifth cycles. IFN-γ levels in the serum 
of mice treated with either PD-1 NVs or aPD-L1 were sig-
nificantly increased (Figure 3f), while TNF-α levels remained 
unchanged (Figure S6, Supporting Information). The infiltra-
tion of CD8+ T cells in the harvested tumor was analyzed by 
flow cytometry. The percentage and number of activated CD8+ 
T cells were significantly increased in tumor collected from 
mice treated with either PD-1 NVs or aPD-L1 groups as com-
pared to control group (Figure 3g, h). Similarly, higher den-
sities of CD8+ T cells were detected by immunofluorescence 
in tumors collected from mice treated with either PD-1 NVs 
or aPD-L1 (Figure 3i,j). Finally, after five cycles of treatments, 
blood cell counts showed that lymphocyte and monocyte con-
tents slightly decreased in mice treated with PD-1 NVs, while 
the lymphocyte ratios were not affected (Figure S7a,b, Sup-
porting Information). Additionally, the plasma level of immu-
noglobulin E (IgE) antibody, produced by the immune system 
overreacts to an allergen,[16] did not significantly increase after 
five cycles of the treatment with PD-1 NVs (Figure S8, Sup-
porting Information).
Next, we loaded the IDO inhibitor 1-MT into the PD-1 NVs 
to investigate the combinatorial therapy of IDO inhibitor and 
immune checkpoint blockage. High loading capacity (≈24%, 
drug/protein weight ratio) of 1-MT was achieved by employing 
the electric shock method compared to the traditional incuba-
tion methods (≈16%) (Figure S9a, Supporting Information). 
The release of 1- MT from the PD-1 NVs was also tested. 1-MT 
can be rapidly released from the NVs within 24 h in vitro 
(Figure S9b, Supporting Information). Furthermore, to deter-
mine the inhibitory effect of 1-MT released by 1-MT-loaded 
PD-1 NVs, we performed an IDO inh¡ibition assay using HeLa 
cells that express IDO after IFN-γ stimulation. Remarkably, 
PD-1 NVs loaded with 1-MT had better inhibitory effect com-
pared to the free 1-MT and 1-MT-loaded free NVs (Figure S10, 
Supporting Information).
To demonstrate whether the simultaneous IDO inhibi-
tion and PD-L1 blockade provided by 1-MT-loaded PD-1 NVs 
Figure 4. In vivo suppression of tumor growth by 1-MT-loaded PD-1 NVs. a) Average tumor volumes of the treated mice in different groups as indicated 
(n = 7). Error bar, mean ± s.e.m. b) Survival curves for the mice received different treatment as indicated (n = 10). c) Representative flow cytometry 
plots and d) quantitative analysis of T cells in the tumors from different treatment groups (n = 3). The cells were pregated for positive CD3+ expres-
sion. Error bar, mean ± s.d. e) Immunofluorescence of the tumors showed infiltrated CD4+ T cells and CD8+ T cells. Scar bar: 100 µm. Throughout, 
NS: no significant, *P < 0.05, **P < 0.01, ***P < 0.001; a,d) two two-way ANOVA analyses were carried out to do the analyses. First two-way ANOVA 
with Tukey post-hoc test analysis carried out between the group of free-NVs (G2), PD-1 NVs (G4), 1-MT@NVs (G5), and 1-MT@PD1- NVs (G7). The 
two factors considered were 1-MT and PD-1. The second two-way ANOVA with Tukey post-hoc test carried out between the groups of the PBS control 
(G1), aPD-L1, 1-MT (G3), and aPD-L1+1-MT (G6). The two factors in this model were 1-MT and aPD-L1 or b) by Log-Rank (Mantel-Cox) test.
enhance antitumor activity, B16F10-luc tumor bearing mice 
were treated with PBS (Group 1), free NVs (Group 2), free 
1-MT (Group 3), PD-1 NVs (Group 4), 1-MT-loaded free NVs
(Group 5), 1-MT plus aPD-L1 (Group 6) and 1-MT-loaded PD-1
NVs (Group 7) every 3 d for five cycles. Tumor growth was
monitored by measuring both bioluminescence signals and
sizes of the tumors. We found high response rate in the mice
treated with free 1-MT and 1-MT-loaded free NVs, however,
limited suppression of tumor growth was observed (Figure 4a;
Figures S11 and S12, Supporting Information). This non-
ideal efficacy may be because multiple immune suppression
mechanisms exist within the TME. Notably, PD-1 NVs had
better antitumor effects as compared to 1-MT (Figure 4a;
Figures S11 and S12, Supporting Information). The mice
treated with 1-MT plus aPD-L1 exhibited significantly delayed
progress of the melanoma tumors (Figure 4a; Figures S11 and
S12, Supporting Information). Importantly, treatment with
1-MT-loaded PD-1 NVs showed a high response rate to the
melanoma tumor, which was much more efficient than the
treatment with 1-MT or PD-1 NVs alone (Figure 4a; Figures
S11 and S12, Supporting Information), and are comparable to
the treatment with 1-MT plus aPD-L1 (Figure 4a; Figures S11
and S12, Supporting Information). Furthermore, the dual inhi-
bition of IDO and PD-L1 by 1-MT-loaded PD-1 NVs improved
the survival of the treated mice without obvious weight loss
(Figure 4b; Figure S13, Supporting Information). We further
examined the density of the CD8+ T cells in the tumor margin
of different treatment groups. Tumor-infiltrated CD8+ T cells
from tumors in all the treatment groups were harvested and
analyzed by flow cytometry and immunofluorescence. It was
demonstrated that treatment with free 1-MT and 1-MT-loaded
NVs increased the number of infiltrating CD8+ T cells by
≈15–20% compared to the PBS-treated group (Figure 4c,d).
Immunofluorescence staining confirmed that PD-1 and 1-MT-
loaded PD-1 NVs significantly enhanced the density of tumor-
infiltrated CD8+ T cells (Figure 4e). The therapeutic efficacy of 
combination treatment was better than the individual ones. 
Infiltration of CD4+ FoxP3+ T cells was also studied. Notably, 
CD4+ FoxP3+ T cells were reduced in 1-MT-loaded PD-1 NVs 
group as well compared to control group (Figure S14, Sup-
porting Information). Finally, major organs such as liver, spleen, 
kidney, heart, and lung were collected and assessed by immu-
nohistochemistry without showing any obvious sign of organ 
damage (Figure S15, Supporting Information). These data 
revealed that IDO inhibition combined with PD-L1 blockage 
PD-1 NVs significantly disrupted the immunosuppression of 
TME, which enhanced the elimination of cancer cells by the 
host’s immune system.
In summary, we engineered cellular nanocarriers displaying 
PD-1 receptors that effectively bind to PD-L1 on the tumor cells 
and disrupt the PD-1/PD-L1 inhibitory axis. PD-L1 blockade by 
PD-1 NVs significantly enhanced the immune response against 
the melanoma tumor in vivo. Furthermore, PD-1 NVs could 
also be adapted to carry a variety of therapeutics to achieve a 
synergistic efficacy. IDO inhibition and PD-L1 blockade were 
achieved by 1-MT-loaded PD-1 NVs. The disruption of dual 
immune tolerance mechanisms in tumors remarkably sup-
pressed the melanoma tumor growth in vivo. Thus, PD-L1 
blockade by PD-1 cellular NVs provides a promising strategy 
that leverages functions of both delivery vehicles and encapsu-
lated drugs for enhancing immunotherapy.[17]
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